interleukin-12
Trials 53 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04388033 Background | Dec 2020 → Dec 2022 | glioblastoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04357821 Background | Aug 2020 → Jun 2026 overdue | HIV infectious disease | University of California, San Francisco | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-18 | Akeso | 康方生物爱达罗®（依若奇,IL-12/IL-23）治疗中重度斑块状银屑病适应症获批上市 akesobio.com ↗ |
| 2024-03-28 | Gilead Sciences | Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program gilead.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 63 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interleukin 12 | “pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly)” PMID 17846226 ↗ Sep 200727“interleukin-12 (IL-12) and is delivered by electroporation combined with intramuscular injection (IM-EP)” PMID 26761518 ↗ Feb 2016 “Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients” NCT00057486 ↗ |
| Known as | Edodekin alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03030378 ↗ |
| Known as | IL-12 | “The purpose of this study is to see if it is safe and effective to add interleukin-12 (IL-12) to the standard drug combination (paromomycin plus azithromycin) used to treat...” NCT00001128 ↗19“Interleukin-12 (IL-12) facilitates cytolytic T-cell responses, enhances the lytic activity of natural killer (NK) cells, and induces the secretion of interferon gamma...” PMID 11756154 ↗ Jan 2002 “This study will test the safety and effectiveness of a drug called interleukin-12 (IL-12) in fighting severe infectious (other than tuberculosis) caused by a group of bacteria...” NCT00001911 ↗ “Interleukin-12 (IL-12) is a potent immunopotentiator of T-cell function, and has been shown in phase I clinical trials to be tolerable.” PMID 14984966 ↗ Mar 2004 “The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma.” PMID 19243818 ↗ Feb 2009 “ARM II: Patients receive vaccination as in arm I with an admixture of recombinant interleukin-12 (IL-12) on days 1, 22, and 50.” NCT01307618 ↗ “pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly)” PMID 17846226 ↗ Sep 2007 “IL-12 (interleukin-12) is a protein found naturally in the body that is thought to boost the immune system.” NCT00000896 ↗ “Patients receive interleukin-12 (IL-12) subcutaneously twice a week (at least 3 days apart) for 6 months.” NCT00019188 ↗ “Interleukin-12 (IL-12) is a cytokine with effects on immune function and hematopoiesis.” PMID 11211153 ↗ Jan 2001 “Interleukin-12 (IL-12) is a central, regulatory cytokine in cell-mediated immunity.” NCT00001763 ↗ “IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12)” NCT04357821 ↗ “Interleukin-12 (IL-12) DNA adjuvant” NCT02431767 ↗ |
| Known as | IL-12 gene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00406939 ↗ |
| Known as | IL-12 pDNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01859325 ↗ |
| Known as | interleukin-12 gene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00072098 ↗ |
| Known as | NSC # 672423 | “A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion” NCT00003439 ↗ |
| Known as | pIL-12 | “Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions” NCT02531425 ↗ |
| Known as | recombinant human interleukin 12 | “A Phase I, Double-Blind, Randomized, Placebo-Controlled Trial of Recombinant Human Interleukin-12 (rhIL-12) in HIV-Infected Subjects With Less Than 50 CD4+ T Cells and Subjects...” NCT00000857 ↗2“recombinant human interleukin-12 (rhIL-12) administered by intraperitoneal infusion” NCT00003439 ↗ “a new schedule of i.v. recombinant human interleukin 12 (rhIL-12)” PMID 10815886 ↗ May 2000 |
| Known as | recombinant interleukin-12 | “Biological: recombinant interleukin-12” NCT00003439 ↗ |
| Known as | rhIL-12 | “A Phase I, Double-Blind, Randomized, Placebo-Controlled Trial of Recombinant Human Interleukin-12 (rhIL-12) in HIV-Infected Subjects With Less Than 50 CD4+ T Cells and Subjects...” NCT00000857 ↗4“A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic...” NCT00057486 ↗ “recombinant human interleukin-12 (rhIL-12) administered by intraperitoneal infusion” NCT00003439 ↗ “a new schedule of i.v. recombinant human interleukin 12 (rhIL-12)” PMID 10815886 ↗ May 2000 “interleukin-12 (rhIL-12)” NCT00003412 ↗ |
| Action | Activate | “IL-12 stimulates interferon gamma” NCT00057486 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-12 (rhIL-12)” NCT00000857 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT00000857 ↗ |